Esperion Therapeutics (ESPR) said Monday it reached a settlement with Micro Labs USA and its affiliate, Micro Labs, resolving a patent dispute over a proposed generic version of its cholesterol-lowering drug, Nexletol.
Under the terms of the agreement, Micro Labs agreed not to market a generic version of Nexletol in the US before April 19, 2040, except under limited circumstances typically included in such settlements.
Esperion said the litigation it filed against Micro Labs has now been resolved. However, patent lawsuits against several other generic drugmakers, including Accord Healthcare, Alkem Laboratories, Aurobindo Pharma, Dr. Reddy's Laboratories (RDY), Hetero USA, MSN Pharmaceuticals, Renata, and Sandoz, remain ongoing.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。